Guangdong Provincial People's Hospital
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1946-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
210
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (142 trials with phase data)• Click on a phase to view related trials
Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
- Conditions
- Lung Carcinoma
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07170046
Development and Validation of a Novel Myocardial Infarction Prediction Model Based on ECG-AI
- Conditions
- Acute Myocardial Infarction (AMI)ElectrocardiographyArtifical Intelligence
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 150000
- Registration Number
- NCT07163767
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Community Exercise Treating Effect on Cardiopulmonary Disease Patients
- Conditions
- Coronary Heart Disease (CHD)Heart FailureCardiomyopathyCOPDBronchial AsthmaThoracic TumorsRespiratory FailureCardiopulmonary Diseases
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT07154355
- Locations
- 🇨🇳
Department of Rehabilitation Medicine Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou, Guangdong, China
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
- Conditions
- Renal Anemia of Chronic Kidney Disease
- Interventions
- Drug: Pegmolesatide 2mg SCDrug: Pegmolesatide 4mg SCDrug: Pegmolesatide 6mg SC
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT07136792
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳Longyan First Hospital, Longyan, Fujian, China
🇨🇳Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, Fujian, China
Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform
- Conditions
- MACECardiac DeathNon-fatal Myocardial InfarctionUnplanned Repeat RevascularizationCardiac RehospitalizationStroke
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 200000
- Registration Number
- NCT07130968
- Prev
- 1
- 2
- 3
- 4
- 5
- 42
- Next
News
Henlius Presents Comprehensive Serplulimab Data at ASCO 2025, Demonstrating Broad Efficacy Across Multiple Cancer Types
Shanghai Henlius Biotech presented results from over ten studies of serplulimab (HANSIZHUANG) at the 2025 ASCO Annual Meeting, covering lung and gastrointestinal cancers with promising efficacy data.
Breakthrough Diagnostic Tools for Early Fatty Liver Disease Detection: AI and Blood Tests Show Promise
New AI technology developed at University of Washington has identified hundreds of undiagnosed fatty liver disease cases by analyzing existing imaging scans, with 83% of patients with evidence of the disease lacking formal diagnosis.